Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07848191 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

Name: Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis — clinical trial record (NCT07848191)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorMadrigal Pharmaceuticals, Inc.

Started2026-09

View on ClinicalTrials.gov ↗

Madrigal Pharmaceuticals, Inc.

9 trials monitored

See all monitored trials

NASH / MASH

645 trials monitored

See 22 trials at risk

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)

Trial Details

NCT Number	NCT07848191
Lead Sponsor	Madrigal Pharmaceuticals, Inc.
Conditions	MASH - Metabolic Dysfunction-Associated Steatohepatitis
Enrollment	150 participants
Start Date	2026-09
Primary Completion	2027-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-09-29